AI-generated summary
The authors review stem cell research in chronic obstructive pulmonary disease (COPD) and pulmonary emphysema. They report that few human translational studies exist, so the rationale for clinical trials rests largely on limited in vitro and animal work. They conclude that stem cell therapy remains an area of active research and that its potential side effects are underestimated.
- Who or what was studied
- patients with chronic obstructive pulmonary disease and/or pulmonary emphysema
- Limits stated in the abstract
- The abstract notes few human translational studies, reliance on limited in vitro and animal data, and an incompletely characterized stem cell population.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.